During the 18-month treatment period , the primary outcome occurred in 6 of 184 patients ( 3.3 % ) in the warfarin group and in 25 of 187 ( 13.5 % ) in the placebo group ( hazard ratio [ HR ] , 0.22 ; 95 % CI , 0.09-0 .55 ; P = .001 ) .